Scientists track breast cancer Drug's journey through healthy women
NCT ID NCT04940026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study gave a single dose of a radioactive-labeled version of the experimental breast cancer drug amcenestrant to 6 healthy postmenopausal women. The goal was to track how the drug is absorbed, broken down, and eliminated from the body. The results will help guide future dosing and development of the drug for breast cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amcenestrant (also known as SAR439859)
- What this could lead to
- This study helps researchers understand how amcenestrant moves through the body, which is important for future breast cancer treatment dosing.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. It only looks at drug processing, not whether the drug works against cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number 8260001
Nottingham, NG11 6JS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates